Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Inventory: 2021-2025

Historic Inventory for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $41.4 million.

  • Kiniksa Pharmaceuticals International's Inventory rose 44.34% to $41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.4 million, marking a year-over-year increase of 44.34%. This contributed to the annual value of $26.4 million for FY2024, which is 15.29% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Inventory stood at $41.4 million for Q3 2025, which was down 14.08% from $48.2 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Inventory's 5-year high stood at $48.2 million during Q2 2025, with a 5-year trough of $2.2 million in Q1 2021.
  • Its 3-year average for Inventory is $30.3 million, with a median of $27.3 million in 2024.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Inventory spiked by 504.07% in 2022 and then fell by 19.10% in 2025.
  • Kiniksa Pharmaceuticals International's Inventory (Quarterly) stood at $3.7 million in 2021, then surged by 487.73% to $21.6 million in 2022, then skyrocketed by 44.09% to $31.1 million in 2023, then dropped by 15.29% to $26.4 million in 2024, then surged by 44.34% to $41.4 million in 2025.
  • Its Inventory stands at $41.4 million for Q3 2025, versus $48.2 million for Q2 2025 and $22.1 million for Q1 2025.